Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
100 participants
Study Classification
OBSERVATIONAL
Study Start Date
2020-11-15
Study Completion Date
2024-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To determine the specific population of critically ill septic patients who benefit most from cytokine adsorption therapy with the HA-380 cartridge. Benefit of the treatment will be assessed on the basis of:
* The scope of the effect of cytokine adsorption therapy in this specific population of critically ill patients expressed by cytokine variability within the patients
* The scope of cytokine changes in passing the adsorption cartridge my measuring cytokine levels in the patient's blood directly before passing through the cartridge and directly after having passed through the cartridge.
* The scope of changes in organ dysfunction expressed by SOFA scores that are repeatedly calculated during the treatment with cytokine adsorption and then daily until day 7 of the ICU treatment.
* The scope of changes on cellular function on immune cells in serum samples taken before and after cytokine adsorption therapy.
* The scope of removal of anti-infective drugs from the blood in passing through the cytokine adsorption cartridge by measuring antibiotic drug levels in the patients blood during the cytokine adsorption therapy
* 30 day and 90 day mortality and location status in survivors
* The scope of the effect of cytokine adsorption therapy in this specific population of critically ill patients expressed by cytokine variability within the patients
* The scope of cytokine changes in passing the adsorption cartridge my measuring cytokine levels in the patient's blood directly before passing through the cartridge and directly after having passed through the cartridge.
* The scope of changes in organ dysfunction expressed by SOFA scores that are repeatedly calculated during the treatment with cytokine adsorption and then daily until day 7 of the ICU treatment.
* The scope of changes on cellular function on immune cells in serum samples taken before and after cytokine adsorption therapy.
* The scope of removal of anti-infective drugs from the blood in passing through the cytokine adsorption cartridge by measuring antibiotic drug levels in the patients blood during the cytokine adsorption therapy
* 30 day and 90 day mortality and location status in survivors
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Extracorporeal Cytokine Hemoadsorption in Septic Shock in Critically Ill Cirrhotics
NCT03866083
Septic Shock
UNKNOWN
NA
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
NCT04395911
AKI
ARDS
COVID
COMPLETED
NA
Cytokine Adsorption in Severe, Refractory Septic Shock
NCT04910893
Septic Shock
Cytokine Storm
COMPLETED
NA
Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis
NCT04280497
Sepsis
RECRUITING
NA
Adjuvant Therapy With CytoSorb in Refractory Septic Shock
NCT04013269
Septic Shock
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Medical Problem Sepsis, a syndrome of physiologic, pathologic, and biochemical abnormalities induced by infection. It is a major public health concern, accounting for more than $20 billion (5.2%) of total US hospital costs in 2011. Sepsis has shown an increase in incidence most likely due to a combination of aging patient populations with more comorbidities and greater recognition. Sepsis is by conservative estimates a leading cause of mortality and morbidity in critical illness with long term sequelae for survivors.
Underlying to sepsis is a multifaceted host response to an infecting pathogen that may be significantly amplified by endogenous factors and is defined by a nonhomeostatic, dysregulated host response to the infection with a potential lethality that is considerably in excess of that straightforward infection. In the early phases, an overshoot of pro-inflammatory mediators is often observed, caused by pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). High levels of pro- and anti-inflammatory cytokines are both associated with increased mortality. Blocking of overproduction of these cytokines using monoclonal anti- bodies targeting specific cytokines such as tumor necrosis factor-α (anti-TNF-α) have not demonstrated mortality benefits in larger trials.
Therefore, an approach to decrease cytokine overproduction by using extracorporeal blood purification has previously been examined. Initial trials using Polymyxin B showed favorable results for markers of critical care treatment with a reduction of vasopressor dosage and higher ratios oxygen partial pressure to inspired oxygen. A larger randomized trial by Payenne however did not show any improvement of organ dysfunction or reduction in mortality by using Polymycin B hemoperfusion.
A recent trial on the effect of the CytoSorb adsorption device using Interleucin-6 (IL-6) levels as marker of efficacy did also not find an effect of mortality, improved organ dysfunction or in fact a reduction of circulating IL-6 levels. However, in this trial the baseline cytokine levels were only moderately increased to begin with suggesting use of a device within a suboptimal patient population.
As no more approved specific therapies to treat sepsis, exist following the withdrawal of recombinant activated protein C (Xigris; Eli Lilly, USA) from the market in 2011 following the results of the PROWESS-SHOCK trial and the pathophysiologic basis for mechanisms in sepsis due to an excess cytokine release are sound, the extracorporeal removal of cytokines remains a promising therapeutic target given the correct patient population.
2. Principal research question and novel aspects Within the trials addressing removal of excess cytokines, the selection of patients and timing of the intervention has been difficult, and results have not been conclusive. Data on the patient population which might benefit most in regard to the aspects of cytokine levels removed and organ failure or progressive organ dysfunction averted are sparse or non-existent. Even the largest randomised trial so far was active for 3 years in recruiting 100 patients out of 580 patients screened. This trial failed to show a positive effect on the primary endpoint of IL-6 removal as well as on secondary endpoints of morbidity or 30 day mortality. However, in this small trial there was a very low median cytokine level measured at baseline and randomisation which might be associated with the consecutive failure to detect a reduction in circulating cytokines. The question remains, whether this trial identified a patient population that was going to benefit from such a therapy to begin with. Post-hoc analyses of another trial, the Euphrates trial showed that there might be positive signal for reduced mortality in patients with an endotoxin activity that was in a mid-range and not at the highest end of the spectrum.
We therefore aim to undertake an observational trial to examine the effect of treating sepsis according to the surviving sepsis campaign guidelines and using extracorporeal cytokine removal looking at circulating cytokine levels and development of new or worsening organ dysfunction in patients with sepsis or septic shock who show highly increased IL-6 levels.
3. HA 330 and HA 380 Hemoperfusion Cartridge The HA type resin cartridge (Jafron Industries, China) is an extracorporeal hemoperfusion device that uses neutral microporous resin, and it has been proven to specifically absorb different media- tors such as bilirubin and cytokines.
The HA380 HA 330 and HA 380 resin cartridges haves the ability to absorb various medium-sized factors, including most inflammatory cytokines (IL-1, IL-6, IL-8, IL-10 and TNF-a) and haves therefore lately been used in the treatment of patients with sepsis in China with several case reports demonstrating promising results on the clinical course of treated patients. Furthermore, there pooled there is emerging data that this therapeutic concept is efficienct and helpful in adequately selected patient populations.
The HA 380 cartridge is the CE-labeled updated version of the HA-330 cartridge which features a larger surface area of the resin beads increasing the overall capacity and thus potential efficacy of the device.
The HA 380 Hemoperfusion Cartridge works using Van der Waals interaction between resin molecular groups and adsorbed substances. Unlike the CytoSorb device, these are incorporated into the resin molecule by a molecular sieve effect of the 3D network structure and the lipophilic hydrophobicity of the molecular group. Therefore, the pass-through effect in removing cytokines is expected to be larger and more sustained, as previously adsorbed cytokines will not again be released by continued blood flow or movement of the device. The range of adsorption is shown in figure 1. The device described has a CE label and is approved for treatment in a variety of clinically situations including but not limited to intra-operative use in cardiac surgery, intoxication, liver failure and sepsis. Compared to other available devices which could be used in the same settings this cartridge offers superior flow characteristics, less flow resistance and a higher capacity of cytokine removal. The effect of combining a standard treatment course of sepsis according to the Surviving Sepsis Campaign guidelines with extracorporeal cytokine removal however is not well examined overall.
In the investigator center, the investigators have therefore undertaken a retrospective pilot observational trial of 15 patients in which the using the HA 380 330 device was used as a rescue therapy in therapy in 15 patients with septic shock and multi-organ failure refractory to conventional treatment. In this trial of extremely ill patients the investigators found a significant difference between hospital survivors and non-survivors in circulating IL-6, IL-10 and TNF-alpha levels after 8 hours of treatment with the HLA 3380 cartridge. However, the overall variation of cytokine levels at baseline and the variation of changes from baseline during therapy were rather large. The sample size was too small to infer any causality or undertake multi-variate analysis.
Underlying to sepsis is a multifaceted host response to an infecting pathogen that may be significantly amplified by endogenous factors and is defined by a nonhomeostatic, dysregulated host response to the infection with a potential lethality that is considerably in excess of that straightforward infection. In the early phases, an overshoot of pro-inflammatory mediators is often observed, caused by pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). High levels of pro- and anti-inflammatory cytokines are both associated with increased mortality. Blocking of overproduction of these cytokines using monoclonal anti- bodies targeting specific cytokines such as tumor necrosis factor-α (anti-TNF-α) have not demonstrated mortality benefits in larger trials.
Therefore, an approach to decrease cytokine overproduction by using extracorporeal blood purification has previously been examined. Initial trials using Polymyxin B showed favorable results for markers of critical care treatment with a reduction of vasopressor dosage and higher ratios oxygen partial pressure to inspired oxygen. A larger randomized trial by Payenne however did not show any improvement of organ dysfunction or reduction in mortality by using Polymycin B hemoperfusion.
A recent trial on the effect of the CytoSorb adsorption device using Interleucin-6 (IL-6) levels as marker of efficacy did also not find an effect of mortality, improved organ dysfunction or in fact a reduction of circulating IL-6 levels. However, in this trial the baseline cytokine levels were only moderately increased to begin with suggesting use of a device within a suboptimal patient population.
As no more approved specific therapies to treat sepsis, exist following the withdrawal of recombinant activated protein C (Xigris; Eli Lilly, USA) from the market in 2011 following the results of the PROWESS-SHOCK trial and the pathophysiologic basis for mechanisms in sepsis due to an excess cytokine release are sound, the extracorporeal removal of cytokines remains a promising therapeutic target given the correct patient population.
2. Principal research question and novel aspects Within the trials addressing removal of excess cytokines, the selection of patients and timing of the intervention has been difficult, and results have not been conclusive. Data on the patient population which might benefit most in regard to the aspects of cytokine levels removed and organ failure or progressive organ dysfunction averted are sparse or non-existent. Even the largest randomised trial so far was active for 3 years in recruiting 100 patients out of 580 patients screened. This trial failed to show a positive effect on the primary endpoint of IL-6 removal as well as on secondary endpoints of morbidity or 30 day mortality. However, in this small trial there was a very low median cytokine level measured at baseline and randomisation which might be associated with the consecutive failure to detect a reduction in circulating cytokines. The question remains, whether this trial identified a patient population that was going to benefit from such a therapy to begin with. Post-hoc analyses of another trial, the Euphrates trial showed that there might be positive signal for reduced mortality in patients with an endotoxin activity that was in a mid-range and not at the highest end of the spectrum.
We therefore aim to undertake an observational trial to examine the effect of treating sepsis according to the surviving sepsis campaign guidelines and using extracorporeal cytokine removal looking at circulating cytokine levels and development of new or worsening organ dysfunction in patients with sepsis or septic shock who show highly increased IL-6 levels.
3. HA 330 and HA 380 Hemoperfusion Cartridge The HA type resin cartridge (Jafron Industries, China) is an extracorporeal hemoperfusion device that uses neutral microporous resin, and it has been proven to specifically absorb different media- tors such as bilirubin and cytokines.
The HA380 HA 330 and HA 380 resin cartridges haves the ability to absorb various medium-sized factors, including most inflammatory cytokines (IL-1, IL-6, IL-8, IL-10 and TNF-a) and haves therefore lately been used in the treatment of patients with sepsis in China with several case reports demonstrating promising results on the clinical course of treated patients. Furthermore, there pooled there is emerging data that this therapeutic concept is efficienct and helpful in adequately selected patient populations.
The HA 380 cartridge is the CE-labeled updated version of the HA-330 cartridge which features a larger surface area of the resin beads increasing the overall capacity and thus potential efficacy of the device.
The HA 380 Hemoperfusion Cartridge works using Van der Waals interaction between resin molecular groups and adsorbed substances. Unlike the CytoSorb device, these are incorporated into the resin molecule by a molecular sieve effect of the 3D network structure and the lipophilic hydrophobicity of the molecular group. Therefore, the pass-through effect in removing cytokines is expected to be larger and more sustained, as previously adsorbed cytokines will not again be released by continued blood flow or movement of the device. The range of adsorption is shown in figure 1. The device described has a CE label and is approved for treatment in a variety of clinically situations including but not limited to intra-operative use in cardiac surgery, intoxication, liver failure and sepsis. Compared to other available devices which could be used in the same settings this cartridge offers superior flow characteristics, less flow resistance and a higher capacity of cytokine removal. The effect of combining a standard treatment course of sepsis according to the Surviving Sepsis Campaign guidelines with extracorporeal cytokine removal however is not well examined overall.
In the investigator center, the investigators have therefore undertaken a retrospective pilot observational trial of 15 patients in which the using the HA 380 330 device was used as a rescue therapy in therapy in 15 patients with septic shock and multi-organ failure refractory to conventional treatment. In this trial of extremely ill patients the investigators found a significant difference between hospital survivors and non-survivors in circulating IL-6, IL-10 and TNF-alpha levels after 8 hours of treatment with the HLA 3380 cartridge. However, the overall variation of cytokine levels at baseline and the variation of changes from baseline during therapy were rather large. The sample size was too small to infer any causality or undertake multi-variate analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Sepsis
Septic Shock
Multiple Organ Failure
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
OTHER
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. \>18 years of age
2. diagnosis of sepsis or septic shock with at least 2 organ-dysfunctions defined by SOFA score
3. baseline serum IL-6 \> 1000 pg/ml, IL-10 levels \>250 pg/ml or TNF-alpha levels \> 100 ng/l. The baseline IL-6 measurement must be on the same calendar day that the cytokine adsorption is started, the baseline IL-10 or TNF-alpha can be taken up to 36h before because of higher turn-around times for these tests.
4. need for CRRT or ECMO therapy
2. diagnosis of sepsis or septic shock with at least 2 organ-dysfunctions defined by SOFA score
3. baseline serum IL-6 \> 1000 pg/ml, IL-10 levels \>250 pg/ml or TNF-alpha levels \> 100 ng/l. The baseline IL-6 measurement must be on the same calendar day that the cytokine adsorption is started, the baseline IL-10 or TNF-alpha can be taken up to 36h before because of higher turn-around times for these tests.
4. need for CRRT or ECMO therapy
Exclusion Criteria
1. Solid organ malignancies with or without treatment
2. Participation or enrollment in another clinical study within 30 day
3. Pregnant and lactating females If women of childbearing potential will be enrolled, a pregnancy test will be performed by assessing the value of ß-HCG in the routinely drawn blood and or urine.
4. Patient has been committed to an institution by legal or regulatory order
5. Participation in a parallel interventional clinical trial
6. The subject received an investigational drug within 30 days prior to inclusion into this project
2. Participation or enrollment in another clinical study within 30 day
3. Pregnant and lactating females If women of childbearing potential will be enrolled, a pregnancy test will be performed by assessing the value of ß-HCG in the routinely drawn blood and or urine.
4. Patient has been committed to an institution by legal or regulatory order
5. Participation in a parallel interventional clinical trial
6. The subject received an investigational drug within 30 days prior to inclusion into this project
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RWTH Aachen University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alexander Kersten
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital RWTH Aachen
Aachen, North Rhine-Westphalia, Germany
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Germany
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Torio CM, Andrews RM. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011. 2013 Aug. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-. Statistical Brief #160. Available from http://www.ncbi.nlm.nih.gov/books/NBK169005/
Reference Type
BACKGROUND
Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013 May;41(5):1167-74. doi: 10.1097/CCM.0b013e31827c09f8.
Reference Type
BACKGROUND
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013 Feb;41(2):580-637. doi: 10.1097/CCM.0b013e31827e83af.
Reference Type
BACKGROUND
Vincent JL, Marshall JC, Namendys-Silva SA, Francois B, Martin-Loeches I, Lipman J, Reinhart K, Antonelli M, Pickkers P, Njimi H, Jimenez E, Sakr Y; ICON investigators. Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. Lancet Respir Med. 2014 May;2(5):380-6. doi: 10.1016/S2213-2600(14)70061-X. Epub 2014 Apr 14.
Reference Type
BACKGROUND
Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010 Oct 27;304(16):1787-94. doi: 10.1001/jama.2010.1553.
Reference Type
BACKGROUND
Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC; GenIMS Investigators. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007 Aug 13-27;167(15):1655-63. doi: 10.1001/archinte.167.15.1655.
Reference Type
BACKGROUND
Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995 Mar 22-29;273(12):934-41.
Reference Type
BACKGROUND
Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009 Jun 17;301(23):2445-52. doi: 10.1001/jama.2009.856.
Reference Type
BACKGROUND
Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, Pottecher J, Joannes-Boyau O, Martin-Lefevre L, Jabaudon M, Mimoz O, Coudroy R, Ferrandiere M, Kipnis E, Vela C, Chevallier S, Mallat J, Robert R; ABDOMIX Group. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015 Jun;41(6):975-84. doi: 10.1007/s00134-015-3751-z. Epub 2015 Apr 11.
Reference Type
BACKGROUND
Schadler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, Marx G, Putensen C, Spies C, Jorres A, Quintel M, Engel C, Kellum JA, Kuhlmann MK. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. PLoS One. 2017 Oct 30;12(10):e0187015. doi: 10.1371/journal.pone.0187015. eCollection 2017.
Reference Type
BACKGROUND
Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012 May 31;366(22):2055-64. doi: 10.1056/NEJMoa1202290. Epub 2012 May 22.
Reference Type
BACKGROUND
Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, Palevsky PM, Weisberg LS, Schorr CA, Trzeciak S, Walker PM; EUPHRATES Trial Investigators. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. JAMA. 2018 Oct 9;320(14):1455-1463. doi: 10.1001/jama.2018.14618.
Reference Type
BACKGROUND
Hu XB, Gao HB, Liao ME, He MR. [The use of HA330-II microporous resin plasma adsorption in the treatment of chronic severe hepatitis]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007 Dec;19(12):760-1. No abstract available. Chinese.
Reference Type
BACKGROUND
Li G, Yang B, Li C, Chen Y, Guo X, He B, Zhang Y, Dai R. [Studies on adsorption of the organic phosphorus pesticide with the macroporous resin]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2000 Dec;17(4):369-72. Chinese.
Reference Type
BACKGROUND
Gruda MC, Ruggeberg KG, O'Sullivan P, Guliashvili T, Scheirer AR, Golobish TD, Capponi VJ, Chan PP. Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb(R) sorbent porous polymer beads. PLoS One. 2018 Jan 25;13(1):e0191676. doi: 10.1371/journal.pone.0191676. eCollection 2018.
Reference Type
BACKGROUND
Bonavia A, Groff A, Karamchandani K, Singbartl K. Clinical Utility of Extracorporeal Cytokine Hemoadsorption Therapy: A Literature Review. Blood Purif. 2018;46(4):337-349. doi: 10.1159/000492379. Epub 2018 Sep 3.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-058
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19
NCT04344080
COMPLETED
NA
Therapeutic Plasmaexchange in Early Septic Shock
NCT04231994
COMPLETED
PHASE2
Effect of Sepsis Adsorption Column on Syndecan-1 and Mortality
NCT07033910
COMPLETED
Safety and Efficacy of Procalcitonin Guided Antibiotic Therapy in Adult Intensive Care Units (ICU's)
NCT01139489
COMPLETED
NA
Extracorporeal Cytokine Removal in Patients With Septic Shock in an Adult Intensive Care Unit
NCT04231695
UNKNOWN
Effects of Renal Replacement Therapy With Hemoadsoption in Patients With Sepsis
NCT04533256
COMPLETED
CLinical Efficacy of Hemoperfusion With a Cytokine Adsorber in Norepinephrine-Resistant SEptic Shock
NCT05136183
UNKNOWN
NA
Adrenomedullin and Outcome in Severe Sepsis and Septic Shock
NCT02393781
COMPLETED
Effects of Norepinephrine and Volume Expansion in Capillary Refill Time in Septic Shock
NCT04870892
UNKNOWN
Efficacy Study of CytoSorb Hemoperfusion Device on IL-6 Removal in ARDS/ALI Patients With Sepsis
NCT00559130
COMPLETED
NA
Hydrocortisone for Prevention of Septic Shock
NCT00670254
COMPLETED
PHASE3
Citrate Versus Heparin Anticoagulation: Effect on Molecules Clearances
NCT01839578
UNKNOWN
NA
Efficacy & Safety of Resatorvid in Adults With Severe Sepsis
NCT00143611
COMPLETED
PHASE3
Resuscitation Strategies in Septic Shock
NCT02150512
UNKNOWN
NA
Therapeutic Plasma Exchange in Adult Patients With Severe Sepsis
NCT04057872
COMPLETED
PHASE1
Beta-Lactam InfusioN Group Study
NCT03213990
COMPLETED
NA
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock
NCT00604214
COMPLETED
PHASE3
Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock
NCT05726825
RECRUITING
NA
Plasmaexchange in Early Septic Shock
NCT03065751
UNKNOWN
NA
Citrulline in Severe Sepsis
NCT01474863
COMPLETED
PHASE2
Circulatory Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis
NCT04644302
COMPLETED
Cytokine Hemadsorption in Covid 19 Patients With Bacterial Sepsis
NCT04920851
UNKNOWN
Improvement of Cerebrovascular Autoregulation in Patients With Septic Shock Due to Cytokine Elimination
NCT04259567
UNKNOWN
NA
Pharmacokinetic of Ceftriaxone in Septic ICU Patients
NCT00449800
UNKNOWN
PHASE4
Efficacy and Safety of Electroacupuncture for ICU Sepsis Patients
NCT06666946
RECRUITING
NA